Drugs / D3L-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07667842 | Jul 2026 → Nov 2027 expected | — | D3 Bio (Wuxi) Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D3L-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07667842 ↗ |
| Action | Inhibit | “anti-TIGIT/anti-PVRIG” NCT07667842 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT07667842 ↗ |